Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alfa-2a vs Interferon Alfa-2a in ESRD Patients with Chronic Hepatitis C
NCT00172809Phase 4Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Jul 2005
- Primary completion
- Jun 2006
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoints: Sustained Virological Response and Sustained Histological Response. Started Jul 2005; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00172809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172809.